The escalating demand for non-invasive liquid biopsy stems from its transformative impact on cancer diagnostics and treatment monitoring. Over the past decade, invasive techniques for diagnosing and monitoring cancers are slowly been replaced by non-invasive methods such as liquid biopsy. Liquid biopsies consist of isolating tumor-derived entities such as circulating tumor cells, circulating tumor DNA, and tumor extracellular vesicles present in the body fluids of patients with cancer, followed by an analysis of genomic and proteomic data. Non-invasive liquid biopsy techniques have emerged as a significant approach for cancer diagnostics, driving significant demand in oncology. Liquid biopsy is the analysis of biomarkers, such as circulating tumor DNA (ctDNA), Circulating Tumor Cells (CTC’s), or exosomes in blood or other body fluids, without invasive tissue biopsies.
Access Full Report @ https://www.databridgemarketresearch.com/pt/reports/global-liquid-biopsy-market
Data Bridge Market Research analyses that the Global Liquid Biopsy Market is expected to grow with a CAGR of 16.8% in the forecast period from 2024 to 2031, and is expected to reach USD 7,429.32 million by 2031.
Key Findings of the Study
Integration of Artificial Intelligence (AI) and Machine Learning
Liquid biopsy-based approaches offer many new opportunities to measure molecular biomarkers for diagnosing, prognosis, and monitoring disease. Artificial Intelligence (AI), such as machine learning, and its ability to identify signatures of specific disease states in multiplexed data will be key to taking advantage of the new molecular information that microchip-based diagnostics can extract.
Researchers in liquid biopsy are developing technologies to measure sparse molecular biomarkers shed from inaccessible tissue in easily sampled bodily fluids, such as urine, blood, saliva, sweat, feces, and tears. The last decade has seen great progress in this field, and there is a growing list of circulating indicators, such as circulating cells, microvesicles, nucleic acids, proteins, and metabolites that can be detected. Machine learning encompasses a set of computational techniques widely applied in many fields to reduce large numbers of measurements into lower-dimensional, more useful outputs. Machine learning algorithms have been increasingly applied to liquid biopsy data to aid disease diagnosis, prediction, and medical decision-making in recent years. A growing set of studies use these approaches to identify signatures in multiple circulating biomarkers for various applications, including cancer, tuberculosis, dengue fever, heart disease, liver disease, brain disease, and diabetes.
Report Scope and Market Segmentation
|
Report Metric
|
Details
|
|
Forecast Period
|
2024 to 2031
|
|
Base Year
|
2023
|
|
Historic Years
|
2022 (Customizable to 2016-2021)
|
|
Quantitative Units
|
Revenue in USD Million, Volume in Units, Prices in USD
|
|
Segments Covered
|
Product (Instruments, Consumables & Accessories, and Services & Software), Biomarker Type (Circulating Tumor Cells (CTCS), Circulating Cell-Free DNA (CFDNA), Cell-free RNA, Extracellular Vesicles, Exosomes, and Others), Sample Type (Blood Sample Based, Urine Sample Based, Saliva & Other Tissue Fluid Sample-Based, Fecal Based Sampling, and Others), Analytical Type (Molecular, Proteomics, and Histology/Imaging), Application Type (Cancer Applications and Non-Cancer Applications), Clinical Application (Routine Screening, Patient Work-Up, Therapy Selection, Treatment Monitoring, Recurrence Monitoring, and Others), Technology (Multi-Gene Parallel Analysis, and Single-Gene Analysis), End User (Hospitals, Reference Laboratories, Diagnostic Centers, Research Centers & Academic Institutes, and Others), Distribution Channel (Direct Tender, Third Party Distributor, and Others)
|
|
Countries Covered
|
U.S., Canada, Mexico, Germany, France, Italy, Spain. U.K., Switzerland, Netherlands, Russia, Turkey, Sweden, Belgium, Rest of Europe, Japan, China, India, South Korea, Australia, Singapore, Thailand, Indonesia, Malaysia, Philippines, Rest of Asia-Pacific, Brazil, Argentina, Rest of South America, South Africa, UAE, Saudi Arabia, Kuwait, and Rest of Middle East and Africa
|
|
Market Players Covered
|
F. Hoffmann-La Roche Ltd (Switzerland), Guardant Health (U.S.), Exact Sciences Corporation (U.S.), QIAGEN (U.S.), Thermo Fisher Scientific Inc. (U.S.), Illumina Inc. (U.S.), Natera, Inc. (U.S.) NeoGenomics Laboratories Bio-Rad Laboratories, Inc. (U.S.), Laboratory Corporation of America Holdings (U.S.), mdxhealth (Belgium), PathAI (U.S.), STRECK (U.S.), Menarini Silicon Biosystems (Italy), BIOCEPT, INC. (U.S.) Sysmex Inostics Inc. (Subsidiary of Sysmex Corporation) (U.S.) Fluxion Biosciences Inc. (U.S.), Epic Sciences (U.S.), Predicine (U.S.), ANGLE plc (U.K.), and Oncocyte Corporation (U.S.), among others
|
|
Data Points Covered in the Report
|
In addition to the insights on market scenarios such as market value, growth rate, segmentation, geographical coverage, and major players, the market reports curated by the Data Bridge Market Research also include depth expert analysis, patient epidemiology, pipeline analysis, pricing analysis, and regulatory framework.
|
Segment Analysis
The global liquid biopsy market is categorized into nine notable segments based on product, biomarker type, sample type, analytical type, application type, clinical application, technology, end user, and distribution channel.
- On the basis of product, the market is segmented into instruments, consumables & accessories, and services & software
In 2024, the consumables & accessories segment is expected to dominate the global liquid biopsy market
In 2024, the consumables & accessories segment is expected to dominate the global liquid biopsy market with a 51.63% market share as these products are utilized in various regions and more advanced technologies are available.
- On the basis of biomarker type, the market is segmented into Circulating Tumor Cells (CTC’s), Circulating Cell-Free DNA (CFDNA), cell-free RNA, extracellular vesicles, exosomes, and others
In 2024, the Circulating Tumor Cells (CTC’S) segment is expected to dominate the global liquid biopsy market.
In 2024, the Circulating Tumor Cells (CTC’S) segment is expected to dominate the global liquid biopsy market with a 51.59% market share as it is widely popular and shows precise and accurate results.
- On the basis of sample type, the market is segmented into blood sample-based, urine sample-based, saliva & other tissue fluid-based, and others. In 2024, the blood sample-based segment is expected to dominate the market with a 55.03% market share
- On the basis of analytical type, the market is segmented into molecular, proteomics, and histology/imaging. In 2024, the molecular segment is expected to dominate the market with a 55.51% market share
- On the basis of application type, the market is segmented into cancer applications and non-cancer applications. In 2024, the cancer applications segment is expected to dominate the market with a 76.95% market share
- On the basis of clinical application, the market is segmented into routine screening, patient work-up, therapy selection, treatment monitoring, recurrence monitoring, and others. In 2024, the routine screening segment is expected to dominate the market with a 40.09% market share
- On the basis of technology, the market is segmented into multi gene parallel analysis and single gene analysis. In 2024, the multi gene parallel analysis segment is expected to dominate the market with a 77.52% market share
- On the basis of end user, the market is segmented into hospitals, reference laboratories, diagnostic centers, research centers & academic institute, and others. In 2024, the hospitals segment is expected to dominate the market with a 55.94% market share
- On the basis of distribution channel, the market is segmented into direct tender, third party distributor, and others. In 2024, the direct tender segment is expected to dominate the market with a 65.77% market share
Major Players
Data Bridge Market Research analyzes F. Hoffmann-La Roche Ltd (Switzerland), Guardant Health (U.S.), Exact Sciences Corporation (U.S.), QIAGEN (U.S.), and Thermo Fisher Scientific Inc. (U.S.) as the market players in global liquid biopsy market.
Market Developments
- In January 2022, Exact Sciences Corporation announced the acquisition of Prevention Genetics, a genetic testing laboratory, to complement its advanced cancer diagnostics portfolio and support its entrance into hereditary cancer testing (HCT). This is expected to lead to increased revenue in the future
- In January 2022, QIAGEN announced its new Biotech Grants program winners, an initiative driven by the company's commitment to building strong partnerships with biotechnology and pharma businesses and helping them succeed in the market. This has helped the company in revenue growth
- In August 2022, Bio-Rad Laboratories announced the acquisition of Curiosity Diagnostics, sp.z.o.o. which is a pre-commercial platform company that used to develop a sample-to-answer, rapid diagnostics PCR system for the molecular diagnostics market. This acquisition will help Bio-Rad Laboratories to expand its business in the diagnostics segment.
- In August 2022, F. Hoffmann-La Roche Ltd. announced the launch of a Digital LightCycler System, a next-generation digital PCR system that helps clinical researchers better understand the nature of a patient's cancer, genetic disease or genetic disease, or infection. This system is designed for laboratories performing highly sensitive and precise DNA and RNA analysis in oncology and infectious diseases. This product launch has helped the company in revenue growth.
- In September 2022, Guardant Health, Inc., a leading precision oncology company, announced the introduction of Guardant INFINITY, a next-generation liquid biopsy that provides new, multi-dimensional insights into the complexities of tumor molecular profiles and immune response to advance cancer research and therapy development. This has helped the company in revenue growth.
Regional Analysis
The countries covered in this market report U.S., Canada, Mexico, Germany, U.K., France, Russia, Italy, Spain, Turkey, Poland, Belgium, Netherlands, Switzerland, Denmark, Sweden, Norway, Finland, rest of Europe, China, Japan, India, Australia, South Korea, New Zealand, Singapore, Thailand, Philippines, Malaysia, Indonesia, Vietnam, Taiwan, rest of Asia-Pacific, Brazil, Argentina, rest of South America, Saudi Arabia, U.A.E., South Africa, Egypt, Qatar, Kuwait, Oman, Bahrain, and rest of Middle East And Africa.
As per Data Bridge Market Research analysis:
North America is expected to dominate the global liquid biopsy market
North America is expected to dominate the market owing to the high demand for hemodynamic monitoring in the region and the rise in healthcare expenditure.
Asia-Pacific is estimated to be the fastest-growing region in the market
Asia-Pacific is estimated to be the fastest-growing region in the market is due to the growing adoption of advanced technology and the launch of new products in this region.
For more detailed information about the global liquid biopsy market report, click here – https://www.databridgemarketresearch.com/pt/reports/global-liquid-biopsy-market
